摘要
Rheumatoid arthritis(RA)is an inflammatory disease accompanied by abnormal synovial microenvironment(SM).Sesquiterpene lactones(SLs)are the main anti-inflammatory ingredients of many traditional herbs utilized in RA treatment.α-Methylene-γ-butyrolactone(α-M-γ-B)is a core moiety that widely exists in natural SLs.This study was designed to investigate the anti-arthritic potential ofα-M-γ-B as an independent small molecule in vitro and in vivo.α-M-γ-B exhibited stronger electrophilicity and anti-inflammatory effects than the other six analogs.α-M-γ-B inhibited the production of pro-inflammatory mediators via repolarizing M1 macrophages into M2 macrophages.The transcriptome sequencing suggested thatα-M-γ-B regulated the immune system pathway.Consistently,α-M-γ-B attenuated collagen type II-induced arthritic(CIA)phenotype,restored the balance of Tregs-macrophages and remodeled SM via repolarizing the synovial-associated macrophages in CIA mice.Mechanistically,althoughα-M-γ-B did not prevent the trans-nucleus of NF-κB it interfered with the DNA binding activity of NF-κB via direct interaction with the sulfhydryl in cysteine residue of NF-κB p65,which blocked the activation of NF-κB.Inhibition of NF-κB reduced the M1 polarization of macrophage and suppressed the synovial hyperplasia and angiogenesis.α-M-γ-B failed to ameliorate CIA in the presence of N-acetylcysteine or when the mice were subjected to the macrophage-specific deficiency of Rela.In conclusion,α-M-γ-B significantly attenuated the CIA phenotype by directly targeting NF-κB p65 and inhibiting its DNA binding ability.These results suggest thatα-M-γ-B has the potential to serve as an alternative candidate for treating RA.The greater electrophilicity ofα-M-γ-B,the basis for triggering strong anti-inflammatory activity,accounts for the reason whyα-M-γ-B is evolutionarily conserved in the SLs by medical plants.
基金
support by the National Natural Science Foundation of China(82260801)
China Postdoctoral Science Foundation(2023M730815,China)
Excellent Young Talents Plan of Guizhou Medical University(2023110,China)
the Guizhou Provincial Scientific and Technologic Innovation Base([2023]003,China)
the High Level Innovation Talents(GCC[2023]048,China)
Science and Technology Development Fund,Macao SAR(0159/2020/A3,China)
Guizhou Provincial Science and Technology Project(ZK[2024]152,China)
Guizhou Provincial Health Commission Science and Technology Foundation(gzwkj2023-153,China)are gratefully acknowledged.